Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 11/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 6/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 8/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 8/20 | 0.45 |
| ▸ | USP2 | O75604 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | TSHR | P16473 | 3/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.42 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4871324 | 0.90 | CYP3A4 (0.44) | CYP3A4CYP2C19MAPK1MEN1KMT2A | |
| SCHEMBL4863815 | 0.90 | L3MBTL1 (0.53) | MEN1KMT2AALDH1A1TSHRCYP1A2 | |
| SCHEMBL4866342 | 0.90 | PDK2 (0.44) | MAPK1ALDH1A1TSHRPDK2ALOX15 | |
| SCHEMBL4867474 | 0.87 | USP2 (0.43) | CYP3A4CYP2C19MAPK1MEN1KMT2A | |
| SCHEMBL4863081 | 0.86 | MEN1 (0.46) | CYP2C19MEN1KMT2AL3MBTL1CHRM4 | |
| SCHEMBL4863798 | 0.81 | OPRL1 (0.44) | — | |
| SCHEMBL4866314 | 0.81 | L3MBTL1 (0.51) | MEN1KMT2AALDH1A1TSHRCYP1A2 | |
| SCHEMBL4871392 | 0.80 | OPRL1 (0.41) | — | |
| SCHEMBL4867503 | 0.80 | PDK2 (0.42) | TSHRPDK2L3MBTL1ALOX15CHRM4 | |
| SCHEMBL4867904 | 0.79 | OPRL1 (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050165037-A1 | Process for producing cyclic thioether and synthetic intermediate thereof | SANKYO COMPANY, LIMITED (JP) | 2005-07-28 | — | — | US | claimed |
| EP-1533314-A1 | PROCESS FOR PRODUCING CYCLIC THIOETHER AND SYNTHETIC INTERMEDIATE THEREOF | Sankyo Company, Limited (JP) | 2005-05-25 | — | — | EP | claimed |
| US-7396930-B2 | making spiro(benzo(c)thiophene-1 (3H),4'-piperidine) derivatives; involves reacting a mercapto compound with a 2-halophenylalkyl halide, reacting with an alkyllithium, then N-ethoxycarbonyl-4-piperidone, dehydration and cyclization; industrial scale; novel intermediates to neurokinin receptor antagonist | SANKYO COMPANY, LIMITED (JP) | 2008-07-08 | — | — | US | disclosed |
| US-20050165037-A1 | Process for producing cyclic thioether and synthetic intermediate thereof | SANKYO COMPANY, LIMITED (JP) | 2005-07-28 | — | — | US | disclosed |
| EP-1533314-A1 | PROCESS FOR PRODUCING CYCLIC THIOETHER AND SYNTHETIC INTERMEDIATE THEREOF | Sankyo Company, Limited (JP) | 2005-05-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050165037-A1 | Process for producing cyclic thioether and synthetic intermediate thereof | SULT1E1, TST, TMT1A | CYP3A4 36/4885CYP2C19 295/4885MAPK1 1770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.